Literature DB >> 23316119

Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.

Loretta J Nastoupil1, Christopher R Flowers.   

Abstract

Entities:  

Year:  2012        PMID： 23316119      PMCID： PMC3541037          DOI： 10.1016/j.cmonc.2012.09.019

Source DB:  PubMed          Journal:  Community Oncol        ISSN： 1548-5315


× No keyword cloud information.
  42 in total

1.  Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

Authors:  T Lissitchkov; G Arnaudov; D Peytchev; Kh Merkle
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.553

2.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

Authors:  S Ibrahim; M Keating; K A Do; S O'Brien; Y O Huh; I Jilani; S Lerner; H M Kantarjian; M Albitar
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

3.  Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival.

Authors:  J R Neilson; R Auer; D White; N Bienz; J J Waters; J A Whittaker; D W Milligan; C D Fegan
Journal:  Leukemia       Date:  1997-11       Impact factor: 11.528

4.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

Authors:  William G Wierda; Swaminathan Padmanabhan; Geoffrey W Chan; Ira V Gupta; Steen Lisby; Anders Osterborg
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

6.  Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.

Authors:  Maria Ilaria Del Principe; Giovanni Del Poeta; Francesco Buccisano; Luca Maurillo; Adriano Venditti; Antonella Zucchetto; Rita Marini; Pasquale Niscola; Maria Antonietta Irno Consalvo; Carla Mazzone; Licia Ottaviani; Paola Panetta; Antonio Bruno; Riccardo Bomben; Giovanna Suppo; Massimo Degan; Valter Gattei; Paolo de Fabritiis; Maria Cantonetti; Francesco Lo Coco; Domenico Del Principe; Sergio Amadori
Journal:  Blood       Date:  2006-04-06       Impact factor: 22.113

7.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Authors:  K R Rai; C E Freter; R J Mercier; M R Cooper; B S Mitchell; E A Stadtmauer; P Santábarbara; B Wacker; L Brettman
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

8.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; William G Wierda; Ruth LaPushin; Susan M O'Brien; Stefan Faderl; Mary L Browning; Michael J Keating
Journal:  Eur J Haematol       Date:  2007-12-21       Impact factor: 2.997
View more
  2 in total

Review 1.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

2.  Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Authors:  John C Byrd; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Paul M Barr; Richard R Furman; Thomas J Kipps; Patrick Thornton; Carol Moreno; Marco Montillo; John M Pagel; Jan A Burger; Jennifer A Woyach; Sandra Dai; Remus Vezan; Danelle F James; Jennifer R Brown
Journal:  Blood       Date:  2019-03-06       Impact factor: 25.476
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.